Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that CD274 amplification, Wild type ALK, and Wild type EGFR status confers therapeutic sensitivity to Pembrolizumab in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR mutations or ALK translocations.
This statement is based on a regulatory approval from the Health Service Executive:
First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.